The association of the treatment with glucagon-like peptide-1 receptor agonist exenatide or insulin with cardiovascular outcomes in patients with type 2 diabetes: a retrospective observational study (Q35041308)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	The association of the treatment with glucagon-like peptide-1 receptor agonist exenatide or insulin with cardiovascular outcomes in patients with type 2 diabetes: a retrospective observational study	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

6 August 2017

The association of the treatment with glucagon-like peptide-1 receptor agonist exenatide or insulin with cardiovascular outcomes in patients with type 2 diabetes: a retrospective observational study (English)

1 reference

Europe PubMed Central

6 August 2017

type 2 diabetes

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

object named as

Sanjoy K Paul

1

0 references

author name string

Kerenaftali Klein

2

1 reference

Europe PubMed Central

6 August 2017

David Maggs

3

1 reference

Europe PubMed Central

6 August 2017

Jennie H Best

4

1 reference

Europe PubMed Central

6 August 2017

language of work or name

0 references

publication date

24 January 2015

1 reference

Europe PubMed Central

6 August 2017

Cardiovascular Diabetology

1 reference

Europe PubMed Central

6 August 2017

14

1 reference

Europe PubMed Central

6 August 2017

10

1 reference

Europe PubMed Central

6 August 2017

copyright license

Creative Commons Attribution 4.0 International

1 January 2015

1 reference

April 2022 Public Data File from Crossref

copyright status

0 references

https://scigraph.springernature.com/pub.10.1186/s12933-015-0178-3

0 references

Exendin-4 ameliorates cardiac ischemia/reperfusion injury via caveolae and caveolins-3.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4314769

8 July 2018

Exenatide enhances INS-1 rat pancreatic β‑cell mass by increasing the protein levels of adiponectin and reducing the levels of C-reactive protein

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4314769

8 July 2018

Exendin-4 regulates lipid metabolism and fibroblast growth factor 21 in hepatic steatosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4314769

8 July 2018

Exenatide induces aortic vasodilation increasing hydrogen sulphide, carbon monoxide and nitric oxide production

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4314769

8 July 2018

Alogliptin after acute coronary syndrome in patients with type 2 diabetes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4314769

8 July 2018

Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4314769

8 July 2018

Standards of medical care in diabetes--2013

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4314769

8 July 2018

Extra-pancreatic effects of incretin-based therapies: potential benefit for cardiovascular-risk management in type 2 diabetes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4314769

8 July 2018

The effectiveness of implementing an electronic health record on diabetes care and outcomes.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4314769

8 July 2018

Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4314769

8 July 2018

Novel GLP-1 receptor agonists for diabetes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4314769

8 July 2018

Incretin-based therapies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4314769

8 July 2018

Cardiovascular comorbidities of type 2 diabetes mellitus: defining the potential of glucagonlike peptide-1-based therapies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4314769

8 July 2018

Risk of cardiovascular disease events in patients with type 2 diabetes prescribed the glucagon-like peptide 1 (GLP-1) receptor agonist exenatide twice daily or other glucose-lowering therapies: a retrospective analysis of the LifeLink database

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4314769

8 July 2018

Exenatide suppresses postprandial elevations in lipids and lipoproteins in individuals with impaired glucose tolerance and recent onset type 2 diabetes mellitus

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4314769

8 July 2018

DURATION-1: exenatide once weekly produces sustained glycemic control and weight loss over 52 weeks

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4314769

8 July 2018

Incretin-based therapies: viewpoints on the way to consensus

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4314769

8 July 2018

An algorithm to identify incident myocardial infarction using Medicaid data

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4314769

8 July 2018

GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4314769

8 July 2018

Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4314769

8 July 2018

Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4314769

8 July 2018

Validation of ICD-9 codes with a high positive predictive value for incident strokes resulting in hospitalization using Medicaid health data

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4314769

8 July 2018

The Physiology of Glucagon-like Peptide 1

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4314769

8 July 2018

Newer agents for blood glucose control in type 2 diabetes: summary of NICE guidance.

1 reference

https://api.crossref.org/works/10.1186%2FS12933-015-0178-3

21 January 2018

Longer acting GLP-1 receptor agonists and the potential for improved cardiovascular outcomes: a review of current literature

1 reference

https://api.crossref.org/works/10.1186%2FS12933-015-0178-3

21 January 2018

Effects of HbA1c and weight reduction on blood pressure in patients with type 2 diabetes mellitus treated with exenatide*.

1 reference

https://api.crossref.org/works/10.1186%2FS12933-015-0178-3

21 January 2018

Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion

1 reference

https://api.crossref.org/works/10.1186%2FS12933-015-0178-3

21 January 2018

One-year treatment with exenatide vs. insulin glargine: effects on postprandial glycemia, lipid profiles, and oxidative stress

1 reference

https://api.crossref.org/works/10.1186%2FS12933-015-0178-3

21 January 2018

Cardiovascular safety of combination therapies with incretin-based drugs and metformin compared with a combination of metformin and sulphonylurea in type 2 diabetes mellitus--a retrospective nationwide study

1 reference

https://api.crossref.org/works/10.1186%2FS12933-015-0178-3

21 January 2018

Comparison of GE Centricity Electronic Medical Record database and National Ambulatory Medical Care Survey findings on the prevalence of major conditions in the United States

1 reference

https://api.crossref.org/works/10.1186%2FS12933-015-0178-3

21 January 2018

Use of electronic medical records for clinical research in the management of type 2 diabetes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4314769

25 October 2018

Cardiovascular safety and diabetes drug development

1 reference

https://pubmed.ncbi.nlm.nih.gov/25616979

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Preventive effects of exenatide on endothelial dysfunction induced by ischemia-reperfusion injury via KATP channels

1 reference

https://pubmed.ncbi.nlm.nih.gov/25616979

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1186/S12933-015-0178-3

1 reference

Europe PubMed Central

6 August 2017

Dimensions Publication ID

0 references

1 reference

Europe PubMed Central

6 August 2017

1 reference

Europe PubMed Central

6 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35041308&oldid=1858760248"